Histone deacetylase inhibitors make neuroblastoma cells more sensitive to TRAIL-induced cell death
Author Information
Author(s): Annick Mühlethaler-Mottet, Marjorie Flahaut, Katia Balmas, Katya Auderset, Roland Meier, Jean-Marc Joseph, Nicole Gross
Primary Institution: University Hospital CHUV, Lausanne, Switzerland
Hypothesis
Can histone deacetylase inhibitors (HDACIs) sensitize neuroblastoma cells to TRAIL-induced apoptosis?
Conclusion
HDACIs enhance the apoptotic response of neuroblastoma cells to TRAIL by increasing the activation of apoptotic pathways and altering the balance of pro- and anti-apoptotic proteins.
Supporting Evidence
- HDACIs were shown to activate the mitochondrial pathway and to sensitize NB cells to TRAIL.
- Combined treatments increased the activation of caspases and the inactivation of anti-apoptotic proteins.
- The study demonstrates that HDACIs enhance the apoptotic response by restoring a pro-apoptotic protein ratio.
Takeaway
This study shows that using certain drugs can help cancer cells die when combined with a special treatment, making it easier to fight the cancer.
Methodology
Neuroblastoma cell lines were treated with HDACIs and TRAIL, followed by assays to measure cytotoxicity, apoptosis, and caspase activity.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website